AUTHOR INDEX

Volume 31, 1994

Abratt, R. P., 915
Ackland, S. P., 305
Aikawa, Y., 725
Akine, Y., 735
Albano, K., 165
Ali, M., 743
Allen, P. K., 3
Allison, R., 295
Amols, H., 629
Ang, K. K., 1093, 493, 865
Anscher, M. S., 1237, 1257, 143
Archambeau, J. O., 1171
Arias, F., 813
Arthur, D., 743
Asselain, B., 783
Atkinson, C. H., 305
Avery, L., 485
Ayala, A. G., 237
Ayers, D., 485

Baillet, F., 65
Baker, T. R., 717
Ball, D., 267
Ball, D. L., 273
Balter, J. M., 113
Bartelink, H., 1037, 1043
Barton, M., 227, 371
Bell, D., 315
Benammar, A., 503
Benk, V., 577
Bentel, G. C., 143
Bernier, J., 1043
Bilous, M., 405
Birrell, G., 339
Bishop, J., 267
Blaise, D., 509
Blaivas, M., 461
Blasko, J., 103
Blazar, B. R., 119
Bloomer, W. D., 171
Boisserie, G., 65
Bolla, M., 1043
Bonaventura, A., 305
Boon, P. J., 911
Bosch, W. R., 135
Bourne, R. G., 325
Bowman, L., 799
Bowman, L. C., 485
Boyages, J., 227
Boyages, S. C., 279
Boyle, F., 315
Boyle, W. A., III, 37
Bree, R. L., 113
Breit, S. N., 361
Brickner, T. J., 973
Brierley, J. D., 255
Brook, S., 247
Brown, B. W., 1349
Bruner, D., 1281
Bruner, D. W., 1353
Bryant, G. P., 285
Buchler, D. A., 79
Burke, M.-F., 295
Burt, P. A., 841
Byhardt, R. W., 431

Cabanillas, F., 3
Camel, H. M., 37, 703
Campana, F., 783
Cantell, K., 93
Carroll, P. R., 1257
Cassady, J. R., 1249
Catton, C. N., 255
Chandler, C. L., 541
Chang, A. E., 87
Chao, C. K. S., 37, 929
Char, D. H., 1123
Chen, A. S. J., 31
Chen, Q. M., 65
Cheng, C. W., 157
Chierego, G., 617
Chisela, F., 959
Christie, D., 305
Coffey, D., 477
Coffey, D. H., 485
Cohen, A. M., 553
Coia, L. R., 1213, 129, 567
Colombo, F., 617
Constine, L., III, 1319
Constine, L. S., 1205, 427
Constine, L. S., III, 1037, 1041, 1113, 1165
Cooke, A. L., 777
Cooper, I., 333
Cooper, J. S., 1141, 935
Cora, S., 617
Corn, B. W., 21, 129
Cosset, J.-M., 509
Cowen, D., 509
Cox, J. D., 3, 1341
Cozad, S. C., 43
Creagan, E. T., 827
Crennan, E., 227, 267, 333
Cuillère, J.-C., 509
Cummings, B. J., 255
Curran, W. J., Jr., 453

Dady, P., 305
Daniels, K. A., 119
Das, I. J., 157
Davidson, S. E., 841
Davis, S., 227, 267
D'Costa, I., 333
Deeg, H. J., 1319
Delattre, J.-Y., 65
Deming, R. L., 827
Denekamp, J., 1037, 1043
Denham, J. W., 305
Devineni, V. R., 929
Dickie, G. J., 285
Doldan, R., 765
Dominiak, G., 935
Domínguez, M. A., 813
Donaldson, S. S., 1301
Dreyfus, H., 783
Driscoll, D., 717
Dugan, T. C., 1257
Dusenbery, K. E., 119

Eapen, L., 611
Efird, J., 577
Eifel, P., 1281
Eifel, P. J., 1301
Eisenberg, B. L., 567
Ellerbroek, N., 807
Emami, B., 819
Engel, J., 959
Enker, W. E., 553
Ensminger, W. D., 1237
Epperly, M. W., 171
Epstein, B., 25
Erickson, B., 165
Erickson, B. A., 651
Esteban, J. M., 529

Fajardo, L. F., 1037, 1041, 1205, 1237
Farnan, N., 103, 453
Fein, D. A., 129
Feoktistova, T. P., 535
Fine, B. A., 717
Fine, R. M., 605
Fiore, M. C., 645
Fischbach, A. J., 453
Fisher, B., 777
Fisher, R., 247
Fisher, R.J., 227
Fitzek, M. M., 467
Flay, L. D., 399
Flickinger, J. C., 31
Fontanesi, J., 485, 799
Fossella, F. V., 807
Fourquet, A., 783
Fowble, B., 1015
Fowler, A., 411
Fowler, J. F., 79, 833
Francescon, P., 617
Fu, K., 1141
Fuller, L. M., 3

Galakatos, A. E., 37, 703
Gallagher, S. C., 661
Galvin, J. M., 935
Garcia, D. M., 753
Garden, A. S., 493, 807
Gautier, C., 783
Gebski, V. J., 261
Gerber, R. L., 135
Gerig, L., 611
Gillette, E. L., 1309
Gillette, S. M., 1205, 1309
Gillin, M. T., 165
Girard, A., 611
Glisson, B. S., 807
Gluckman, E., 509
Gonzales-Gonzales, D., 1043
Goodman, P., 255
Gordon, K. B., 1123
Gore, E., 165
Graham, M. V., 135, 819
Graham, P. H., 261
Greenberg, H. S., 461
Greenberg, M., 445
Greenberger, J., 1319
Greenwald, C., 799
Griffin, T. W., 71
Grignon, D. J., 419
Grigsby, P. W., 37, 1281, 703, 875
Grimard, L., 611
Gustafson, G., 791, 943

Hafermann, M. D., 661
Hagemeister, F. B., 3
Hall, E. J., 1005
Halme, M., 93
Halverson, K. J., 753
Hamilton, C. S., 305
Hammond, E. H., 419
Hancock, M. L., 477
Hancock, S. L., 1165
Hanks, G. E., 21, 25, 567, 973, 999
Hanlon, A. L., 973
Harari, P. M., 645
Harms, W. B., 135
Harris, G. J., 651
Harrison, L. B., 103
Hassanein, R. E. S., 43
Healey, G. A., 157
Hempling, R. E., 717
Hendrick, B., 445
Herbert, S. H., 129
Herskovic, A. M., 819
Higgins, P. D., 605
Hill, M., 743
Hill, R. P., 847, 857
Hoffman, H., 445
Hoffman, J. P., 129
Holoye, P. V., 807
Hong, W. K., 807
Hook, C., 227
Hopewell, J. W., 51
Hopkins, K. I., 541
Horiot, J.-C., 1021, 1037
Horiot, J-C., 1043
Houx, P. J., 911
Howard, M., 611
Hug, E. B., 467
Humphreys, R., 445

Hunt, M. A., 25
Hunt, P., 411
Hunter, R. D., 841
Hustu, H. O., 477

Ikeda, H., 735
Illarramendi, J. J., 813
Inakoshi, H., 921
Ingold, J., 791
Ito, T., 921
Iwamoto, R., 661

Jackson, A., 883
Jan, S., 379
Jenkin, D., 445
Jennelle, R. L. S., 109
Jirtle, R. L., 1237
Johnson, J. T., 661
Johnson, N., 227
Johnston, D. A., 865
Jordan, V. C., 833
Joseph, D., 227, 267
Joseph, D. J., 305
Jozsef, G., 635
Junck, L., 461

Kalend, A. M., 171
Kalnicki, S., 31
Kao, M.-S., 37
Karim, A. B. M. F., 571
Kaufman, N., 743
Kavanagh, B., 743
Keane, T. J., 255
Kearsley, J. H., 325
Kefford, R. F., 345
Kemshead, J. T., 541
Keng, P. C., 519
Kersey, J. H., 119
Kessler, M. L., 883
Khoroshkov, V. S., 535
Kim, R. Y., 109
Kinsella, T. J., 79, 645
Kirby, M. C., 593
Kitamura, T., 725
Klein, E. E., 583, 893
Kliauga, P., 629
Knospe, W., 1319
Koh, W.-J., 71, 1281
Komaki, R., 807, 973
Kostjuchenko, V. I., 535
Kovarik, J., 967
Krasin, M. J., 3
Kumar, P., 477, 485, 561, 799
Kun, L. E., 1093, 477, 485, 561, 799
Kuske, R. R., 753
Kutcher, G. J., 1357, 883

Laidlaw, C., 333
Lam, K., 113
Lam, K. S., 179
Lamb, D. S., 305
Lamproglou, I., 65
Lanciano, R. M., 129
Lane, R. G., 179
Langer, M., 179
Langlands, A. O., 261, 405
Laramore, G. E., 423
Lawrence, T. S., 87, 1237, 883
Leborgne, F., 765
Leborgne, J. H., 765
Lee, W. R., 21
Leeper, D. B., 905
Le Pechoux, C., 735
Le Poncin, M., 65
Letschert, J., 1043
Leung, S., 393
LeVeque, F. G., 661
Levine, A., 791
Levitt, R., 827
Lewandowski, M. F., 651
Lichter, A. S., 113
Liebsch, N. J., 467, 577
Liesveld, J. L., 1319
Liew, K. H., 227, 333
Lin, H., 929
Lindstrom, M. J., 833
Ling, C. C., 1357
Littbrand, B., 1043
Little, J. B., 525
Lockett, M. A., 703
López, R., 813
Low, D. A., 135, 583
Luxton, G., 635

Maasilta, P., 93
Maher, M., 783
Mahler, P. A., 1309
Mailliard, J. A., 827
Mallik, R., 411
Mameghan, H., 247
Mameghan, J., 247
Marks, J., 1141
Marks, L. B., 1187, 1257, 143
Martinez, A., 103, 791, 943
Martirosov, K. S., 535
Martínez, E., 813
Massaro, B. M., 651
Matsubara, S., 725
Matsumoto, Y., 921
Matter, R., 791
Matthews, J. H. L., 399
Mattson, K., 93
Mauch, P., 1319
Mazeron, J.-J., 65
McAuley, M., 717
McClure, J. S., 119
McDonald, S., 1187
McDougall, I. R., 1165
McGinnis, L. S., 109
McGlave, P. B., 119
McKay, M. J., 345
McLaughlin, P., 3
McManus, P., 577
Meeuwissen, J. A., 325
Meigooni, A. S., 583
Meredith, R. F., 109
Michalski, J. M., 135
Milpied, N., 509
Minakova, Y. I., 535
Minsky, B. D., 553
Mohan, R., 1357
Mohiuddin, M., 503, 905
Morgan, G., 227
Morgan, G. W., 361
Mornex, F., 1037, 1043
Moros, E. G., 893
Morrill, S. M., 179
Morris, F., 967
Morrison, W. H., 493
Mortimer, J. E., 753
Mosseri, V., 783
Mulcahy, R. T., 833
Mulhern, R. K., 477, 561
Munzenrider, J. E., 467, 577
Murphy, W. K., 807
Murray, K J., 453
Murray, K. J., 651
Muscoplat, C., 661
Mutch, D., 703
Myerson, R. J., 1213, 753, 893

Nag, S., 103
Nair, S., 827
Neglia, J. P., 119
Nelson, D. F., 453
Nichiporov, D. F., 535
Njo, K. H., 571
Noyes, W. R., 79

O'Brien, M., 305
O'Brien, P., 227, 267
O'Connor, N. J., 645
Oda, J.-I., 921
Ogino, I., 725
O'Hara, M. D., 905
Ohmi, K., 735
Okajima, H., 725
Okamoto, N., 725
Opeitum, A., 777
Order, S. E., 953
Ortega, B., 765
Orton, C. G., 1011
O'Sullivan, B., 255
Oswald, M. J., 807
Overgaard, J., 1037
Owen, J. B., 103, 973

Page, M. A., 461
Pajak, T. E., 819
Pajak, T. F., 103, 1341, 1347
Palmer, J. L., 3
Papanastassiou, V., 541
Pappo, A. S., 485
Paty, P., 553
Pavy, J.-J., 1037, 1043
Pendlebury, S., 227, 315
Pendlebury, S. C., 405
Pene, F., 509
Penney, D. P., 519
Perera, F., 777, 959
Perez, C. A., 37, 135, 703, 753, 819, 875
Peters, L. J., 1349, 219, 353, 493, 807, 865
Peters, N. E., 79
Peterson, L. M., 71
Pettinga, J., 791
Pezner, R., 1171
Pfeffer, M. R., 57
Pharm, B., 361
Phillips, T. L., 1037, 1041, 1187
Philpott, G. W., 753
Phipps, R., 519
Piver, M. S., 717
Pizer, B. L., 541
Poisson, M., 65
Pollack, A., 13, 237
Pollard, M. D., 905
Polonski, P. B., 535
Porter, A., 103, 453
Potish, R. A., 1009
Poulsen, M. G., 285
Powers, B. E., 1309
Pratt, G., 227
Price, R. E., 865
Pu, A. T., 461
Purdy, J. A., 135, 583

Quong, G., 227, 333

Radany, E. H., 461
Radford, D., 753
Ramsay, J., 339
Ramsay, N. K. C., 119
Rao, B. N., 485, 799
Raubitschek, A., 529
Regine, W. F., 485, 561, 799, 905
Reiffers, J., 509
Repo, H., 93
Resbeut, M., 509
Richaud, P., 509
Rieke, J. W., 661
Rio, B., 509
Ristola, M., 93
Rivera, G. K., 477, 561
Robbins, M. E. C., 865
Robertson, J. M., 87, 1237, 883
Rodrigues, C. I., 571
Rodriguez, M. A., 3
Roman, D. D., 983
Rosen, I. I., 179
Rosenthal, H. G., 43
Ross, D. A., 461
Roth, J. A., 807
Rubin, P., 1035, 1037, 1041, 1187
Rudoltz, M. S., 503
Rush, C., 753
Russell, A., 1281
Russell, K. J., 71
Rutz, H. P., 525
Ryan, G., 267
Ryan, G. F., 273

Sagerman, R. H., 1123
Saito, A., 921
Saito, M., 921
Sakai, K., 921
Salter, M. M., 109
Sandler, H. M., 113, 461
Sands, M. E., 13
Sarkaria, J. N., 833
Sause, W. T., 1019
Sauter, E. R., 567
Schell, M. C., 605
Schmidt-Ullrich, R., 149, 743
Schultheiss, T. E., 21, 25, 1093
Scott, C., 453
Scott, C. B., 1347
Seski, J., 31

Shapiro, D. N., 799
Shaw, E. G., 827
Sherouse, G. W., 143
Shiell, A., 379
Shin, D. M., 807
Siegal, T., 57
Siegel, J. A., 953
Silin, D. I., 535
Silverman, S., 1141
Simpson, P., 743
Sims, C., 935
Sinclair, W. K., 387
Sklar, C. A., 1113
Slessinger, E. D., 875
Smalley, S. R., 43
Smith, J., 267
Smith, J. G., 273
Smith, M., 929
Smith, R. D., 379
Sohn, J. W., 605
Sondak, V. K., 87
Sonoda, T., 735
Spanos, W., 1281
Speke, A. K., 847, 857
Spencer, D. P., 143
Spencer, S. A., 109
Sperduto, P. W., 983
Spry, N. A., 305
Staker, B. L., 71
Stat, M., 261
Steen, P. D., 827
Steiger, B. W., 661
Stelzer, K. J., 71
Stephens, L. C., 1093, 865
Stetz, J., 1281, 1341
Stewart, J. F., 305
Stewart, J. R., 1205
Stitt, J. A., 79, 1281
Stock, R. G., 31
Straube, W. L., 893
Su, J. Q., 827
Sueyama, H., 921
Sugita, T., 921
Suit, H., 577
Sullivan, J., 1281, 1319
Sumi, M., 735
Sussman, J. J., 87
Svoboda, V. H. J., 967
Swan, F., Jr., 3
Szanto, J., 611

Tanemura, K., 735
Taskinen, E., 93
Taylor, J. M. G., 353
Taylor, M. E., 753
Teague, S. P., 875
Tejedor, M., 813
Ten Haken, R. K., 113, 883
ten Velde, G. P. M., 911
Tepper, J. E., 1213
Testolin, A., 617
Thames, H. D., 865
Thomadsen, B. R., 79
Thomas, G. E., 529
Thomas, P. R. M., 1301
Thompson, J., 333
Thornton, D., 227
Tiver, K. W., 279
Tokuuye, K., 735
Townsend, P. W., 43
Tripcony, L., 285, 295
Trotter, G., 227
Tsuchida, E., 921
Tsunematsu, R., 735
Turner, S. L., 279
Twijnstra, A., 911

Valerdi, J. J., 813
van den Aardweg, G. J. M. J., 51
van Oosterhout, A. G. M., 911
Vatter, A., 445
Velasquez, W. S., 3
Venkatesan, V., 959
Vicini, F., 791
Vilcoq, J. R., 783
von Eschenbach, A. C., 237
Vujaskovic, Z., 1309

Walker, Q., 227, 267
Wallington, M., 227
Wallner, P. E., 953
Ward, W. F., 71
Wasserman, T., 1171, 1353
Wasserman, T. H., 1037, 1041
Weiss, S. A., 87
West, C. M. L., 841
Wheatley, G., 905
White, J., 791
Whitehouse, E. M., 51
Wiesenfeld, M., 827
Willcox, P. A., 915
Williams, P. C., 593
Williamson, J. F., 875
Wimbish, K., 791
Withers, H. R., 1349, 353
Wong, C. S., 255
Wong, J. W., 943
Wong, J. Y. C., 529
Woods, W. G., 119
Wynne, C., 305

Yajima, M., 735
Yamada, T., 735
Yamasita, K., 725
Yan, D., 943
Yashkin, P. N., 535
Yousaf, M., 893
Yu, N., 777

Zagars, G. K., 13, 237
Zananiri, T. F., 541
Zeiger, L. S., 953
Zeitzer, K., 799
Zinovyeva, L. V., 535
Zolotov, V. A., 535
Zubizarreta, E., 765
Zwicker, R. D., 149

SUBJECT INDEX

Volume 31, 1995

A

Accelerated fractionation, 267
Accelerated radiotherapy, 827
"Accept or reject" decisions, 943
Acute lymphoblastic leukemia, 477, 561, 983
Acute morbidity, 25
Acute myeloblastic leukemia, 509
Acute myeloid leukemia, 119
Adenocarcinoma of the prostate, 143
Adjuvant radiation therapy, 305
Adjuvant therapy, 353, 553
Androgen ablation, 13
Anthracycline, 1205
Atherosclerosis, 1205
Attenuation correction, 953
Autologous bone marrow transplantation, 119

B

B-cell markers, 333
Beam hardening, 583
Benign and malignant thyroid neoplasms, 1165
Biologically effective dose, 725
Bladder, 1257
Bladder preservation, 247
Bone, 1141
Bone marrow, 1319
Bone marrow transplantation, 1249
Bone marrow transplant, 509
Boron capture therapy, 171
Bowel complications of radiation, 1213
Brachytherapy, 37, 79, 103, 875, 973
Brain metastases, 273
Brain tumors, 445
Breast, 959
Breast cancer, 295, 305, 339, 405, 765, 783
Breast neoplasm/radiotherapy, 777
Breast radiation response, 1171
Breast tangents, 411
Bremsstrahlung, 953
Bronchoalveolar lavage, 361

C

Cancer, 983
Cancer of the cervix, 399, 725
Capillary, 1205
Capital investment, 379
Carboplatin, 267
Carcinoma of the cervix, 841
Cell-cycle, 525
Cell subpopulations, 519
Central nervous system (CNS) malignancies, 541
Central nervous system abnormalities, 983
Cervical cancer, 79, 109, 717, 973
Cervix, 1281, 875
Cervix cancer, 31
CFU-C, 905
Charged particle therapy, 467
Chemo/radiation interactions, 1249
Chemoradiotherapy, 807, 813
Chemotherapy, 1257, 1281, 305, 315, 485, 799, 911
Chemotherapy effects, 1187
Chemotherapy intensification, 477
Children, 445
Chinese hamster, 535
Chondrosarcoma, 467
CHOP-Bleo, 3
Chordoma, 467, 577
Clamping, 857
Classical pneumonitis, 361
Classification system, 1123
Clinical trials, 353
CNS, 51
Cognitive impairment, 911
Combined modality therapy, 503
Combined treatment, 807
Complications, 37, 1123, 735
Computed tomography, 109
Conformal, 461
Conformal radiation therapy, 935
Conformal radiotherapy, 605
Conformal therapy, 25, 113
Conservative surgery and radiation, 791
Conservative treatment, 295, 765
Coronary artery, 1205
Coronary artery disease, 1205
Cranial irradiation, 65
Craniospinal irradiation, 477, 561
CT planning, 411
CT-simulation, 935
Cultured cells, 535
Curative radiotherapy, 261
Cytokines, 1319, 361

D

Diffuse histopathology, 333
Diffuse large cell lymphoma, 3
Digitally reconstructed radiographs, 935
DNA double strand breaks, 345
DNA repair, 345
Dose, 129
Dose fractionation, 735
Dose prescription, 157
Dose response, 353
Dose tolerance of breast, 1171
Dose tolerance of skin, 1171
Dose-volume histograms, 1249
Dose volume histograms, 883
Dosimetry, 541, 629, 635, 953
DRR, 935
Ductal carcinoma *in situ*, 791
Dynamic wedge, 583

E

Echography, 651
Efficacy, 661
Efficiency, 379
Elderly, 783
Elderly rats, 65
Elective treatment, 353
Electron beam, 157
Electronic portal imaging, 135
Electrons, 893
Endometrial carcinoma, 37
Endometrium, 875
Endothelial cell, 1205
Esophageal adenocarcinoma, 567
Esophageal carcinoma, 921
Esophageal stricture, 1213
Exit dosimetry, 593
Extraocular muscles, 651
Eye, 1123

F

Fallopian tube, 1281
Female reproductive tract, 1281
Fibroblasts, 525
Fibrosis, 1187, 1205, 571
Film dosimetry, 583
Five-fluorouracil, 921
Flow cytometry, 519
Fractionated irradiation, 833, 847, 857
Fractionated radiation therapy, 143

G

Gamma-interferon, 529
Gastric ulceration, 1213
Gastrointestinal radiation injury, 1213
Gene transcription, 361
Giant cell tumor, 467
Gleason grade, 237
Glomerular capillary endothelial cell, 865
Glottis carcinoma, 285
Graves' disease, 1165
Graves' ophthalmopathy, 651
Growing bone, 1301
Growth arrest, 1249
Growth factors, 361, 567
Growth kinetics, 847

H

HDR brachytherapy, 959
Head and neck cancer, 661
Head and neck carcinomas, 503
Head and neck neoplasms, 279
Health physics, 629
Heart, 1205
Hematopoiesis, 1319

Hematopoietic toxicity, 529
Hepatic irradiation, 1237
High dose rate, 79, 165
High-dose-rate afterloader, 967
High dose rate brachytherapy, 735
High dose rate intracavitary brachytherapy, 725
High energy protons, 535
Hodgkin's disease, 227
Hyperfractionated radiation therapy, 453
Hyperfractionated radiotherapy, 827
Hyperfractionation, 493
Hyperrenninemic hypertension, 1249
Hypersensitivity pneumonitis, 361
Hyperthermia, 893, 905
Hyperthyroidism, 1165
Hypertrophy, 1249
Hypopharynx, 493
Hypopituitarism, 1165
Hypothalamus, 1113
Hypothyroidism, 1165, 279
Hypoxia, 857

I

Image display, 135
Image registration, 113
Immobilization device, 143
Implant, 875
Implantation, 959
Induction chemotherapy, 813
Inhalation, 93
Injury, 1257
Intelligence, 983
Interferon-gamma, 827
Interstitial brachytherapy, 149, 393
Intrinsic radiosensitivity, 841
Iododeoxyuridine, 87
Iridium-192, 149
Irradiated lung and heart areas, 411
Irradiation, 703
Irradiation and surgery, 703
Irradiation effect, 1141
Isolated central nervous system relapse, 477
Isolated CNS relapse, 561

K

Kidney, 865

L

Lactate, 525
Larynx, 493
Late effects, 1187, 1237, 1281, 1353
Late effects breast, 1171
Late effects skin, 1171
Late radiation injury, 1309
Learning, 65
Linear accelerator, 635
Linear quadratic formula, 371
Liver, 883
Local control, 503
Localization, 959
Locally advanced nonsmall cell lung cancer, 813
Local recurrence, 247
Long-term follow-up, 973
Long-term results, 813
Low-dose irradiation, 485
Low dose rate, 165
Low grade gliomas, 461
Lung cancer, 267, 273, 819
Lung fibroblasts, 519
Lung functions, 915
Lung irradiation, 915
Lymph node metastases, 31
Lymph node status, 503
Lymphocyte predominant Hodgkin's disease, 333
Lymphocytes, 339

M

Malignant gliomas, 453
Malignant lymphoma, 929
Malignant melanoma, 345
Mammary tumor xenograft, 833
Marrow transplantation, 1319
Measurement variation, 943
Megavoltage on-line imaging, 943
Memory, 65
Merkel cell carcinoma, 325
Mesangial cell, 865
Metastases, 247
Metastatic disease, 43
Micro-dosimetry, 171
Microdosimetry, 629
Microvessel response to irradiation, 1171
Monoclonal antibodies, 171, 529
Monoclonal antibodies (MoAbs), 541
Monte Carlo, 171
Morphometry, 865
MR T2-signal abnormality, 461
Mucosa, 1141
Multicenter trials, 661
Murine tumors, 847
Muscle, 1309
Myocardium, 1205

N

Nasopharyngeal carcinoma, 611
Natural history, 21
Nerve, 1309
Neurocognitive assessment, 561
Neuroendocrine, 1113
Neuroendocrine (Merkel cell) carcinoma, 315
Neuropsychological impairment, 983
Neurotoxicity, 911
Node positive, 13
Nodular, 333
Nonsmall cell, 267
Nonsmall cell lung cancer, 261, 827
Normalization, 157
Normal tissue toxicity, 1301
NTCP, 51, 883
Nuclear grade, 791

O

Ocular adnexa, 1123
Once-weekly irradiation, 783
Optimization, 179, 617
Optimize, 79
Orbit, 1123
Organ preservation, 553
Orthopedic stabilization, 43
Orthovoltage radiotherapy, 571
Osteogenic sarcoma, 467
Ovary, 1281
Overall treatment time, 833
Oxygen radical production, 93

P

^{32}P, 953
Pancreas, 605
Parallel architecture, 883
Pathological fracture, 43
Pathophysiology of irradiated skin, 1171
Patterns of care, 103
Patterns of failure, 461, 765
Pediatric genitourinary malignancy, 393
Pediatric radiation renal tolerance, 1249
Pelvic failure, 109
Pelvic irradiation, 31
Penile induration, 571
Pentoxifylline, 71
Pericarditis, 1205
Pericardium, 1205
Peyronie's disease, 571
Phagocyte, 93
Pharmacokinetics, 93, 541
Pilocarpine, 661
Pituitary, 1113
Ploidy, 841
Pneumonitis, 71
Portal imaging, 593
Posterior pharyngeal wall carcinoma, 611
Postoperative radiotherapy, 43
Potential doubling time, 833
Potential doubling time (T_{pot}), 847
Predictive assays, 841
Preoperative radiation therapy, 87
Primary orbital lymphoma, 929
Primate, 865
Prognosis, 247, 567
Prognostic factors, 765
Prognostic parameters, 743
Proliferation, 525
Prophylactic cranial irradiation, 911
Prostaglandins, 57
Prostate cancer, 13, 21, 25, 237
Prostate movement, 113
Proton irradiation, 535
Proton therapy, 577
Proximal tubule, 865
PSA, 21
PSA doubling time, 21
Psychometric testing, 911
Pulmonary fibrosis, 71, 361
Pulsed field gel electrophoresis, 345

Q

Quality control, 593
Quality of life, 1353, 453
Quantitative SPECT imaging, 953

R

Rabbit, 1205
Radiation, 57, 1123, 1205, 1257, 1281, 273, 295, 493, 651, 661, 865, 893, 905, 983
Radiation dose limit, 387
Radiation fractionation, 799
Radiation hepatitis, 883
Radiation-induced bone sarcomas, 405
Radiation-induced cancer, 387
Radiation-induced heart disease, 1205
Radiation-induced liver disease, 1237
Radiation injury, 71, 1165, 1205
Radiation nephritis, 1249
Radiation nephropathy, 1249
Radiation pneumonitis, 1187, 361
Radiation protection, 387
Radiation sensitivity, 519
Radiation sensitizers, 87
Radiation therapy, 37, 103, 109, 1113, 129, 1301, 135, 1353, 237, 325, 353, 379, 467, 717, 743
Radical radiation therapy, 255
Radioimmunotherapy, 529
Radionuclide therapy, 953
Radiosensitivity, 339
Radiosensitizer, 827
Radiosurgery, 617
Radiotherapy, 3, 13, 21, 43, 227, 247, 267, 279, 285, 315, 371, 399, 503, 577, 617, 629, 735, 777, 819, 921, 973
Radiotherapy technique, 611
RBE, 535
Rectal cancer, 255, 553
Rectal complication, 725
Rectal reference point, 725
Reflectors, 893
Relative biological effectiveness, 535
Remote afterloading, 875
Reoxygenation, 857
Repopulation, 833, 847, 857
Results of therapy, 703
Retroperitoneal, 129
Retroperitoneal sarcoma, 87
Review, 1257
Rhabdomyosarcoma, 485, 799
r-IFN-gamma, 93

S

Safety, 661
Salivary glands, 1141
Salvage cystectomy, 247
Sarcoma, 129
Secondary non-Hodgkin's lymphoma, 333
Serotonin, 57
Severe combined immunodeficient, 905
Sexual dysfunction, 399
Sexuality, 399
Side effects, 399
Simulated annealing, 179
Simulator based CT, 411
Simultaneous, 893
Skin functional unit, 1171
Skin irradiation response, 1171
Skin molds and applicators, 967
Skin scoring, 1171
Skull neoplasm, 577
Small-cell lung cancer, 807
Small cell lung cancer, 911
Soft tissue sarcomas, 405
Spinal cord, 51, 57
Sporadic pneumonitis, 361
Spread out Bragg peak, 535
Stem cells, 1319
Stereotactic radiosurgery, 635
Steroids, 273
Subclinical metastases, 353
Superficial, 893
Surgery, 1281, 285, 325, 399, 485, 799
Surgical staging, 717
Survey, 103
Survival, 445

T

Tamoxifen, 777, 783
Target coverage, 157
Teeth, 1141
Thermoradiotherapy, 893
Thermotolerance, 905
3D radiotherapy, 605
3D treatment planning, 935
Three-dimensional radiation therapy, 461
Thyroid diseases, 1165
Thyroidectomy, 1165
Thyroiditis, 1165
Time-dose factor, 725
Timing of thoracic radiotherapy, 807
Tolerance, 1249, 1257
Tolerance doses and volumes, 1187
Total body irradiation, 119, 1319, 509
Toxicity, 247
Toxicity scoring, 1187
Transitional cell carcinoma, 247
Treatment, 445, 577
Treatment outcome, 929
Treatment planning, 109, 179, 583, 635
Treatment setup variation, 943
Treatment verification, 135
Tumor control, 973
Tumor control probability, 353
Tumor proliferation, 833

U

Ultrasound, 651, 893
Uniformity index, 157
Ureter, 1257
Ureteric obstruction, 247
Urethra, 1257
Uterine cervical carcinoma, 743
Uterine cervix, 703
Uterine cervix carcinoma, 735
Uterus, 1281

V

Vagina, 1281
Vaginal cylinder, 165
Vascular permeability, 57
Veno-occlusive disease, 1237
Virtual simulation, 935
Volume effect, 883
Vulva, 1281

X

Xerostomia, 661